Tegan Cruwys, Georgina C Lee, Alysia M Robertson, Catherine Haslam, Nikola Sterling, Michael J Platow, Elyse Williams, S Alexander Haslam, Zoe C Walter
Therapists who foster social identification build stronger therapeutic working alliance and have better client outcomes
Comprehensive psychiatry
assess risk venous thromboembolism use combined oral contraceptives according progestogen type oestrogen dosenational historical registry based cohort studyfour registries denmarknonpregnant danish women aged 1549 history thrombotic disease followed january 2001 december 2009relative absolute risks first time venous thromboembolismwithin 8010290 women years observation 4307 first ever venous thromboembolic events recorded 4246 included among 2847 67 events confirmed certain compared nonusers hormonal contraception relative risk confirmed venous thromboembolism users oral contraceptives containing 3040 g ethinylestradiol levonorgestrel 29 95 confidence interval 22 38 desogestrel 66 56 78 gestodene 62 56 70 drospirenone 64 54 75 users oral contraceptives levonorgestrel reference adjusting length use rate ratio confirmed venous thromboembolism users oral contraceptives desogestrel 22 17 30 gestodene 21 16 28 drospirenone 21 16 28 risk confirmed venous thromboembolism increased use progestogen pills hormone releasing intrauterine devices oral contraceptives desogestrel gestodene drospirenone anticipated increase risk venous thromboembolism sixfold levonorgestrel threefold absolute risk venous thromboembolism current users former group average 10 per 10000 women years 2000 women would need shift using oral contraceptives desogestrel gestodene drospirenone levonorgestrel prevent one event venous thromboembolism one yearafter adjustment length use users oral contraceptives desogestrel gestodene drospirenone least twice risk venous thromboembolism compared users oral contraceptives levonorgestrel